[IMGN] ImmunoGen, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.64 Change: 0.08 (5.13%)
Ext. hours: Change: 0 (0%)

chart IMGN

Refresh chart

Strongest Trends Summary For IMGN

IMGN is in the medium-term down -50% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the t

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 98.97% Sales Growth - Q/Q-76.34% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.42% ROE-95.13% ROI
Current Ratio5.22 Quick Ratio5.1 Long Term Debt/Equity Debt Ratio0.38
Gross Margin Operating Margin-71.01% Net Profit Margin-72.15% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.43 M Cash From Investing Activities-5.03 M Cash From Operating Activities-26.84 M Gross Profit
Net Profit-30.47 M Operating Profit-25.09 M Total Assets313.82 M Total Current Assets278.11 M
Total Current Liabilities35.81 M Total Debt Total Liabilities278.72 M Total Revenue12.61 M
Technical Data
High 52 week12.95 Low 52 week3.94 Last close4.83 Last change-1.63%
RSI39.32 Average true range0.32 Beta1.44 Volume965.36 K
Simple moving average 20 days-5.45% Simple moving average 50 days-5.21% Simple moving average 200 days-41.12%
Performance Data
Performance Week1.47% Performance Month-2.23% Performance Quart-18.69% Performance Half-47.39%
Performance Year-50.51% Performance Year-to-date0.63% Volatility daily4.16% Volatility weekly9.31%
Volatility monthly19.08% Volatility yearly66.11% Relative Volume259.72% Average Volume2.57 M
New High New Low

News

2019-03-12 08:56:12 | Options Traders Expect Huge Moves in ImmunoGen IMGN Stock

2019-03-10 09:30:01 | ImmunoGen IMGN Down 50.2% Since Last Earnings Report: Can It Rebound?

2019-03-06 12:22:06 | ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates

2019-03-06 12:05:00 | Four Biotech Stocks Setting The Standard on Wednesday

2019-03-06 10:26:03 | Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

2019-03-04 23:38:04 | Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks

2019-03-04 08:06:31 | Why ImmunoGen Tanked on Friday

2019-03-02 12:48:05 | Immunogen Inc IMGN Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-01 13:45:00 | Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint

2019-03-01 12:13:42 | Why ImmunoGen Stock Is Crashing Today

2019-03-01 08:08:23 | Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail

2019-03-01 06:51:00 | Immunogen's stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint

2019-03-01 06:38:56 | ImmunoGen's ovarian cancer drug fails in late-stage study

2019-03-01 06:30:00 | ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer

2019-02-27 17:14:00 | Why ImmunoGen Tumbled 20.3% Today

2019-02-27 16:31:00 | ImmunoGen Announces Multiple Presentations at AACR Annual Meeting

2019-02-22 07:40:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Economic Growth

2019-02-21 08:00:00 | Healthcare Companies Investors are Watching

2019-02-18 14:19:27 | How ImmunoGen, Inc. NASDAQ:IMGN Could Add Value To Your Portfolio

2019-02-12 15:58:00 | ImmunoGen Still Waiting to Take Its Leap "Forward"

2019-02-11 09:29:02 | ImmunoGen IMGN Beats on Earnings & Sales in Q4, Shares Up

2019-02-11 08:53:01 | Options Traders Expect Huge Moves in ImmunoGen IMGN Stock

2019-02-08 21:35:52 | ImmunoGen IMGN Q4 2018 Earnings Conference Call Transcript

2019-02-08 21:20:10 | Edited Transcript of IMGN earnings conference call or presentation 8-Feb-19 1:00pm GMT

2019-02-08 07:45:12 | ImmunoGen IMGN Reports Q4 Loss, Tops Revenue Estimates

2019-02-08 06:47:20 | ImmunoGen: 4Q Earnings Snapshot

2019-02-08 06:30:00 | ImmunoGen Reports Recent Progress and 2018 Operating Results

2019-02-06 18:35:00 | Why ImmunoGen Jumped Almost 14% Today

2019-02-01 10:30:03 | Earnings Preview: ImmunoGen IMGN Q4 Earnings Expected to Decline

2019-01-24 16:30:00 | ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results

2019-01-18 15:00:19 | Have Insiders Been Selling ImmunoGen, Inc. NASDAQ:IMGN Shares This Year?

2019-01-09 07:39:50 | The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study

2019-01-08 16:01:00 | ImmunoGen Announces Sale of Residual Kadcyla Royalties

2019-01-07 17:20:00 | Why ImmunoGen Jumped Today

2019-01-02 08:30:00 | ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-26 16:18:00 | Why ImmunoGen Shot Up 13% Today

2018-12-17 21:52:44 | Hedge Funds Are Betting On ImmunoGen, Inc. IMGN

2018-12-12 07:55:00 | Market Trends Toward New Normal in Marriott International, Duke Energy, ImmunoGen, Newell Brands, Vail Resorts, and Fiserv — Emerging Consolidated Expectations, Analyst Ratings

2018-12-06 14:49:07 | Roche's Kadcyla Halves Death Risk in Breast Cancer Study

2018-12-02 17:51:20 | The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

2018-12-02 09:30:02 | ImmunoGen IMGN Down 7.2% Since Last Earnings Report: Can It Rebound?

2018-12-01 10:31:00 | ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting

2018-11-27 07:32:26 | The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

2018-11-26 16:47:15 | Former Aveo exec resigns as ImmunoGen CFO after fraud verdict

2018-11-26 16:01:00 | ImmunoGen Announces Resignation of Chief Financial Officer

2018-11-25 09:41:17 | The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

2018-11-21 11:23:32 | Former Aveo CFO misled biotech's investors, jury finds

2018-11-20 08:31:01 | Are Options Traders Betting on a Big Move in ImmunoGen IMGN Stock?

2018-11-14 11:35:00 | Healthcare Stocks with Turnaround Potential

2018-11-12 07:32:00 | How Has Cara Therapeutics’ 2018 Performance Shaken Out?